Recombinant Human Serum Albumin in Healthy Subjects

NCT ID: NCT05179265

Last Updated: 2023-01-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-29
• Study Completion Date: 2022-07-07

Brief Summary

This trial adopts a single-center, randomized, double-blind, dose-escalation, placebo-controlled design to evaluate the safety, tolerability, pharmacokinetics, and efficacy of a single administration of recombinant human serum albumin in healthy subjects Kinetics and anti-drug antibody characteristics.

Qualified healthy subjects (both male and female) were screened and enrolled to the four dose levels of 2 g, 5 g, 10 g, and 20 g according to the principle of dose escalation, and 6 out of 8 subjects in each dose group One patient received the test drug, and two received a placebo.

Detailed Description

This trial adopts a single-center, randomized, double-blind, dose-escalation, placebo-controlled design to evaluate the safety, tolerability, pharmacokinetics, and efficacy of a single administration of recombinant human serum albumin in healthy subjects Kinetics and anti-drug antibody characteristics.

Qualified healthy subjects (both male and female) were screened and enrolled to the four dose levels of 2 g, 5 g, 10 g, and 20 g according to the principle of dose escalation. 6 out of 8 subjects in each dose group One patient received the test drug, and two received a placebo. Among them, each case in the first dose (2 g) group was enrolled in the group at least 48 hours apart, and was randomly assigned to receive intravenous administration of the test drug or placebo; the first two subjects in the second, third, and fourth dose groups could serve as sentinels. Enrolled at the same time. One patient received the test drug intravenously, the other received a placebo intravenously, and two sentinel subjects completed a single intravenous drug observation for at least 48 hours. If no severe allergic reaction occurred, the group The other subjects in each case were enrolled in the group at least 48 hours apart, and randomly assigned to receive intravenous administration of the test drug or placebo for a single dose of safety, tolerability, pharmacokinetics, and pharmacodynamics And anti-drug antibody test. All subjects should undergo a skin test before receiving the test drug or placebo intravenously, that is, receive an intradermal injection of about 20 mg of the test drug or placebo, and observe the skin test response: if 1 h after the intradermal injection ( ±10 min) If the subject is red, swollen or indurated at the injection site with a diameter of ≤1.5 cm, intravenous administration can be performed, otherwise the subject will have a positive skin test and cannot receive intravenous administration. Subjects who have a positive skin test will withdraw from the test after completing the inspections and operations specified in the protocol. During the test, whether to adjust the positive standard of the skin test reaction will be determined according to the safety information that has been obtained.

Conditions

Hepatic Ascites

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Control group

0.45 g/bottle，50 mL

Group Type: PLACEBO_COMPARATOR

Human serum albumin

Intervention Type: DRUG

10 g/bottle (20%, 50 mL)

test group

10 g/bottle (20%, 50 mL)

Group Type: EXPERIMENTAL

recombinant human serum albumin

Intervention Type: DRUG

10 g/bottle (20%, 50 mL)

Interventions

recombinant human serum albumin

10 g/bottle (20%, 50 mL)

Intervention Type: DRUG

Human serum albumin

10 g/bottle (20%, 50 mL)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy adults, 18 to 55 years old (including the critical value), male or female;

2. Body weight ≥45 kg, body mass index (BMI) between 18 and 28 kg/㎡ (including the critical value);

3. Throughout the study period (from screening to 3 months after the end of the study), subjects or their spouses voluntarily use effective contraceptive methods, such as abstinence, condoms, intrauterine device (IUD), and double barrier method (such as condoms and diaphragm), and there was no sperm donation plan for men;

4. Be willing to participate in clinical trials and sign Informed Consent Form;

5. Be able to communicate well with researchers and understand and abide by the requirements of this study.

Exclusion Criteria

1. Yeast source antibody positive;

2. Investigators consider that there is a clinically significant drug or food allergy, allergic disease history or allergic constitution (≥2 substance allergies), or explicitly allergic to this product or its similar albumin preparation ingredient;

3. History of clinical serious disease, including but not limited to circulatory systems, endocrine systems, gastrointestinal tract, kidneys, nervous systems, blood systems, immune systems, mental disease and metabolic abnormalities, and investigators consider that not suitable for clinical trials ;

4. History of cardiovascular system disease, including but not limited to vital signs abnormalities (such as systolic pressure <90 mmHg or> 140 mmHg, diastolic pressure <50 mmHg or> 90 mmHg, heart rate <50 bpm or> 100 bpm), severe arrhythmia, Heart failure, unstable angina pectoris, myocardial infarction occurred six months prior to screening ､the tachycardia / translucent that needs drug therapy, three-degree atrioventricular block, QTC interval≥450 ms or electrocardiogram has a clinically significant abnormality;

5. Previous has a chronic infectious disease and the investigators can judge possible affecting the evaluation of the drug in trial;

6. Surgery of diseases having clinical significance within 4 weeks before administration;

7. Difficulties with blood collection or cannot be resistant to venipuncture , history of needle sickness or blood sickness.

8. Alcohol breath test , smoke test or drug urinary screening is positive;

9. Physical examination, vital signs, 12 lead electrocardiogram, laboratory examination (blood routine, urine routine, blood biochemical examination, etc.) found that there is a clinical significance;

10. One or more positive results for human immunodeficiency virus (HIV) antibody, treponema pallidum antibody, hepatitis B surface antigen or hepatitis C antibody;

11. A history of drug abuse, or alcohol abuse ( in other words , drinking more than 14 units of alcohol per week [1 unit=360 mL beer or 45 mL of 40% alcoholic spirits or 150 mL wine]) or smoking history (≥5 per day ), or those who cannot smoke during hospitalization;

12. Those who use any caffeine-rich food or beverages (coffee, tea, cola, chocolate, etc.) within 48 hours before the first administration of the study drug, or who do not agree to prohibit the use of caffeine-rich food or beverages during the trial;

13. Those who have special dietary requirements and cannot follow a unified diet;

14. Those who have been treated with corticosteroids or human plasma products within 4 weeks before the trial drug is administered, and have used any prescription drugs, over-the-counter drugs or herbal medicines within 2 weeks (except external preparations or topical preparations);

15. Participated in any drug clinical trial within 3 months before administration;

16. Those who have donated blood within 4 weeks before dosing or plan to donate blood during the study period or within 4 weeks after the end of the study (>400 mL);

17. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial;

18. Researchers believe that compliance is poor, or those who have other factors that are not suitable for participating in this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Protgen Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bei Hu, Ph.D

Role: STUDY_DIRECTOR

hubei01_pumch@163.com

Locations

Shenzheng Protgen Ltd

Guangdong, Shenzheng, China

Countries

China

Other Identifiers

rHSA 2020-1

Identifier Type: -

Identifier Source: org_study_id